Stem Cell Authority, Ltd.
Stem Cell Authority, Ltd.
Your view on SCAL
Overview
What the company does, where it operates, and who runs it.
About Stem Cell Authority, Ltd.
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Carlzo Bernard Cardwell
- Headquarters
- 123 South Miller Road, Fairlawn, OH, US
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
- CEO
- Carlzo Bernard Cardwell
- Headquarters
- 123 South Miller Road, Fairlawn, OH, US
Stem Cell Authority, Ltd., a technology development company, focuses on the collection and cryogenic preservation of stem cells.
It specializes in the collection and cryogenic preservation of the hematopoietic stem cells from the umbilical cord blood; and the Miracle Mesenchymal stem cells from the Wharton's jelly inside the umbilical cord of a newborn child.
The company's technology enables birthing professionals with a stem cell preservation program to serve their maternity patients in the United States. Stem Cell Authority, Ltd. is based in Fairlawn, Ohio.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Stem Cell Authority, Ltd., and the rating behind it. SCAL last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Stem Cell Authority, Ltd.. Starting points for Stem Cell Authority, Ltd.: beta -1.11 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Stem Cell Authority, Ltd.. Stem Cell Authority, Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Stem Cell Authority, Ltd.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Stem Cell Authority, Ltd.. Stem Cell Authority, Ltd. has reported as a listed company since 2005. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Stem Cell Authority, Ltd. valued side by side against its closest peers. Stem Cell Authority, Ltd. is measured against Medical - Care Facilities peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Stem Cell Authority, Ltd., and how their positions are changing. At a $8,712 market value, institutional positions materially move Stem Cell Authority, Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Stem Cell Authority, Ltd. executives and directors. Shares of Stem Cell Authority, Ltd. have traded between $0.0001 and $0.0045 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Stem Cell Authority, Ltd.. Stem Cell Authority, Ltd. is a $8,712 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Stem Cell Authority, Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Stem Cell Authority, Ltd.. Coverage tracks Stem Cell Authority, Ltd. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.